logo
Wall Street ends lower as investors consider tariff impact on results, economy

Wall Street ends lower as investors consider tariff impact on results, economy

NBC News2 days ago
U.S. stocks ended lower on Tuesday as investors weighed the impact of tariffs after Yum Brands and other companies cited trade duties in their results or outlooks.
The U.S. trade deficit narrowed in June on a sharp drop in consumer goods imports, and the trade gap with China shrank to its lowest in more than 21 years.
In addition, a measure of activity in the U.S. services sector hit stall-speed in July, with businesses saying new import taxes are pushing costs higher.
Shares of KFC parent Yum Brands fell 5.1% after the company missed estimates for the second quarter, as steep trade duties restricted consumer spending.
Caterpillar warned U.S. tariffs would pose significant challenges in the second half of the year and cost it up to $1.5 billion in 2025, but its shares ended up 0.1%.
The comments come at the tail end of the U.S. second-quarter earnings season, in which about 80% of reports from S&P 500 companies are beating analyst profit expectations.
'If you look at results, they are trending above low-bar expectations,' said Terry Sandven, chief equity strategist at U.S. Bank Wealth Management in Minneapolis, Minnesota.
'The impact of tariffs remains a work in progress. We're not seeing any meaningful impact on company profitability with tariffs. We do know, however, that they loom.'
The Dow Jones Industrial Average fell 61.90 points, or 0.14%, to 44,111.74, the S&P 500 lost 30.75 points, or 0.49%, to 6,299.19 and the Nasdaq Composite .IXIC lost 137.03 points, or 0.65%, to 20,916.55.
Trump on Tuesday said the U.S. could impose a ' small tariff ' on pharmaceutical imports before increasing the rate subsequently. He also signaled an announcement on tariffs on semiconductors and chips in the 'next week or so.'
'Today's market action reflects investors that are merely in pause mode,' Sandven said, noting that the backdrop for equities remains constructive for the year.
The S&P 500 and Nasdaq hit a string of record highs recently, and the S&P 500 remains up 7.1% for the year so far.
In other results-related news, Marriott International cut its full-year forecast for revenue growth and profit and signaled slowing travel demand and economic uncertainties. Its stock closed up 0.2%.
While the earnings period is winding down, investors look forward to more key results on Wednesday, with both Walt Disney and McDonald's due to report.
Advancing issues outnumbered decliners by a 1.27-to-1 ratio on the NYSE. There were 158 new highs and 67 new lows on the NYSE.
On the Nasdaq, 2,216 stocks rose and 2,365 fell as declining issues outnumbered advancers by a 1.07-to-1 ratio.
Volume on U.S. exchanges was 16.29 billion shares, compared with the roughly 18.33 billion average for the full session over the last 20 trading days.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

DigitalBridge Reports Second Quarter 2025 Financial Results
DigitalBridge Reports Second Quarter 2025 Financial Results

Yahoo

time20 minutes ago

  • Yahoo

DigitalBridge Reports Second Quarter 2025 Financial Results

BOCA RATON, Fla., August 07, 2025--(BUSINESS WIRE)--DigitalBridge Group, Inc. ("DigitalBridge" or the "Company") (NYSE: DBRG), a leading global alternative asset manager dedicated to investing in digital infrastructure, today announced its financial results for the second quarter of 2025. The earnings presentation is available on the Shareholders section of the Company's website at the following link: Q2 2025 Presentation. Second Quarter 2025 Conference Call The Company will conduct an earnings conference call and presentation to discuss the second quarter 2025 financial results today, Thursday, August 7, 2025, at 8:00 a.m. Eastern Time (ET). A live broadcast will be available on the Shareholders section of the Company's website here. To participate by phone, please dial (844) 826-3035 (U.S.) at least ten minutes prior to the start time (to allow time for registration). International callers should dial (412) 317-5195. A replay will be available starting August 7, 2025, at 12:00 p.m. ET. To access the replay, dial (844) 512-2921 (U.S.), and use conference ID 10200580. International callers should dial (412) 317-6671 and enter the same conference ID number. About DigitalBridge DigitalBridge (NYSE: DBRG) is a leading global alternative asset manager dedicated to investing in digital infrastructure. With a heritage of over 25 years investing in and operating businesses across the digital ecosystem, including cell towers, data centers, fiber, small cells, and edge infrastructure, the DigitalBridge team manages $106 billion of infrastructure assets on behalf of its limited partners and shareholders. For more information, visit: View source version on Contacts Investors:Severin WhiteManaging Director(212) Media:Joele Frank, Wilkinson Brimmer KatcherJon Keehner / Sarah Salky(212) 355-4449dbrg-jf@

Kiora Pharmaceuticals to Showcase Its Retinal Disease Therapeutic Pipeline at The H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
Kiora Pharmaceuticals to Showcase Its Retinal Disease Therapeutic Pipeline at The H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Yahoo

time20 minutes ago

  • Yahoo

Kiora Pharmaceuticals to Showcase Its Retinal Disease Therapeutic Pipeline at The H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Encinitas, California--(Newsfile Corp. - August 7, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that its President and CEO, Brian M. Strem, Ph.D., will showcase the Company's pipeline of therapies targeting inherited and inflammatory retinal diseases at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference. Presentation Details Date: Wednesday, August 13, 2025 Time: 7:00 am Eastern Daylight Time Link: The replay will be available on-demand for 90 days on Kiora's investor relations website. About Kiora Pharmaceuticals Kiora Pharmaceuticals is a clinical-stage biotechnology company developing advanced therapies for retinal disease. We target critical pathways underlying retinal diseases using innovative small molecules to slow, stop, or restore vision loss. KIO-301 is being developed for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of retinal inflammation. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH). In addition to news releases and SEC filings, we expect to post information on our website, and social media accounts that could be relevant to investors. We encourage investors to follow us on X and LinkedIn as well as to visit our website and/or subscribe to email alerts. Forward-Looking Statements Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements include statements relating to, among other things, Kiora's ability to execute on development and commercialization efforts and other regulatory or marketing approval efforts pertaining to Kiora's development-stage products, including KIO-104 and KIO-301, as well as the success thereof, with such approvals or success may not be obtained or achieved on a timely basis or at all, the sufficiency of existing cash and short-term investments on hand to fund operations for specific periods, and the ability to timely complete planned initiatives for 2025, including Phase 2 clinical development of KIO-301 and KIO-104. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, the ability to conduct clinical trials on a timely basis, market and other conditions and certain risk factors described under the heading "Risk Factors" contained in Kiora's Annual Report on Form 10-K filed with the SEC on March 25, 2025 or described in Kiora's other public filings. Kiora's results may also be affected by factors of which Kiora is not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. Kiora expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions, or circumstances on which any such statement is based, except as required by law. Contact: investors@ To view the source version of this press release, please visit 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤

DHI Group Inc (DHX) Q2 2025 Earnings Call Highlights: Surpassing Expectations Amidst Market ...
DHI Group Inc (DHX) Q2 2025 Earnings Call Highlights: Surpassing Expectations Amidst Market ...

Yahoo

time20 minutes ago

  • Yahoo

DHI Group Inc (DHX) Q2 2025 Earnings Call Highlights: Surpassing Expectations Amidst Market ...

Release Date: August 06, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points DHI Group Inc (NYSE:DHX) achieved an adjusted EBITDA of $8.5 million with a margin of 27%, surpassing consensus expectations. Clearance Jobs (CJ) reported strong profitability with an adjusted EBITDA of $6.1 million and a margin of 45%. The acquisition of Agile ATS is expected to enhance the Clearance Jobs platform by integrating a specialized applicant tracking system. The tech job market shows signs of stabilization, with national tech job postings remaining consistent and AI driving increased demand for tech professionals. DHI Group Inc (NYSE:DHX) has proactively managed costs, resulting in significant annual savings and positioning the company for future growth. Negative Points Total revenue for DHI Group Inc (NYSE:DHX) declined by 11% year over year, with total bookings down 10%. DICE faced a challenging environment with bookings down 16% year over year, reflecting cautious hiring and spending by customers. The tech hiring environment remains weak, leading to a reduction in annual revenue guidance for 2025. DICE's average annual revenue per recruitment package customer decreased by 5% year over year. The company experienced churn with smaller customers, impacting both Clearance Jobs and DICE customer counts. Q & A Highlights Warning! GuruFocus has detected 7 Warning Signs with DHX. Q: Can you discuss the booking performance for Clearance Jobs in Q2 and your confidence in returning to growth in the second half of the year? A: (Art Zale, CEO) The second quarter was challenging for Clearance Jobs due to client uncertainty around the federal budget process. However, with the approval of a $1.1 trillion defense budget, confidence has improved, and we expect a more stable environment moving forward. Q: How does the acquisition of Agile ATS fit into the Clearance Jobs platform, and what impact do you expect it to have? A: (Art Zale, CEO) Agile ATS is a natural extension for Clearance Jobs, providing a specialized applicant tracking system for cleared workers. It targets companies with 10 to 250 employees, many of whom lack an ATS. We believe it will enhance customer retention and acquisition, with a price point of $7,000 per subscription annually. Q: After restructuring, how do you plan to stabilize the DICE business in the current tech hiring environment? A: (Art Zale, CEO) We believe the demand environment is stabilizing, with tech job postings remaining consistent. Encouraging signs from staffing and recruiting segments suggest potential growth, as evidenced by recent revenue growth reports from major staffing firms. Q: What percentage of job postings now require AI skills, and how has this changed over time? A: (Art Zale, CEO) As of June, 36% of job postings on DICE required AI skills, up from 10% at the beginning of last year. This surge reflects growing AI adoption across industries, driven by competitive pressures and strategic initiatives. Q: Will the acquisition of Agile ATS impact Clearance Jobs' margins in the second half of the year? A: (Greg Skippers, CFO) There won't be a significant impact on margins in the second half of the year. Revenue from Agile ATS will start flowing in more in 2026, and we expect it to be accretive to Clearance Jobs over time. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store